ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,851.30
-0.16%
S&P ASX All Technology
3,086.00
0.96%
Brent Oil
83.025
-0.60%
US Dollar vs AUD
1.50192
0.21%
Bitcoin
71,174.33
-0.38%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Camurus Ab (0RD1)

  7. Camurus Ab (0RD1) News

0RD1

Camurus Ab (0RD1)

Camurus Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0RD1
DateTimeSourceHeadlineSymbolCompany
17/07/202315:40PR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
17/07/202315:36PR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
24/05/202313:25PR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
24/05/202313:17PR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
16/12/202109:15PR Newswire (US)Braeburn receives new Complete Response Letter for Brixadi in the USLSE:0RD1Camurus Ab
16/09/202119:38PR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
16/09/202119:37PR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
27/06/202102:09PR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
27/06/202102:02PR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
16/06/202108:12PR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
16/06/202108:05PR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
11/05/202101:22PR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
11/05/202101:21PR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
03/05/202116:42PR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
03/05/202116:40PR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
27/03/202100:33PR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
27/03/202100:32PR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
18/12/202018:27PR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
18/12/202018:26PR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
24/06/202022:38PR Newswire (US)Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obe...LSE:0RD1Camurus Ab
24/06/202000:39PR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
24/06/202000:33PR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
02/06/202007:55PR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
02/06/202007:52PR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
15/05/202001:24PR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
15/05/202001:22PR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
07/05/202021:18PR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
07/05/202021:17PR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
02/04/202017:37PR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
02/04/202017:32PR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
 Showing the most relevant articles for your search:LSE:0RD1

Your Recent History

LSE
FJ23
Barclays 27
BIT
F12575
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved